Inicio › Enfermedad de obstrucción pulmonar crónica › Georgia
Ensayos clínicos de Enfermedad de obstrucción pulmonar crónica en Georgia
12 estudios sobre Enfermedad de obstrucción pulmonar crónica buscan participantes en Georgia.
Ciudades en Georgia
Texto oficial del estudio (inglés)
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
ReclutandoFase 4
Edades de 40 a 85 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 15 sept 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- y 1 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
ReclutandoFase 2/3
Edades de 35 a 80 · Todos los sexos · Actualizado el 31 ago 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 26 ago 2026 · NCT06283966To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
ReclutandoFase 2
Edades de 40 a 85 · Todos los sexos · Actualizado el 7 ago 2026 · NCT07684820eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
ReclutandoFase 3
Edades de 40 a 75 · Todos los sexos · Actualizado el 28 jul 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
ReclutandoFase 2
Edades de 35 a 89 · Todos los sexos · Actualizado el 15 may 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- y 1 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 9 abr 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
ReclutandoEstudio observacional
Edades de 50 en adelante · Todos los sexos · Actualizado el 5 ago 2025 · NCT06122077De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.